25 XP   0   0   10

Aytu BioScience Inc
Buy, Hold or Sell?

Let's analyse Aytu BioScience Inc together

PenkeI guess you are interested in Aytu BioScience Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aytu BioScience Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Aytu BioScience Inc

I send you an email if I find something interesting about Aytu BioScience Inc.

Quick analysis of Aytu BioScience Inc (30 sec.)










What can you expect buying and holding a share of Aytu BioScience Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$5.90
Expected worth in 1 year
$3.57
How sure are you?
42.5%

+ What do you gain per year?

Total Gains per Share
$-2.33
Return On Investment
-82.0%

For what price can you sell your share?

Current Price per Share
$2.84
Expected price per share
$2.37 - $3.45
How sure are you?
50%

1. Valuation of Aytu BioScience Inc (5 min.)




Live pricePrice per Share (EOD)

$2.84

Intrinsic Value Per Share

$-18.35 - $7.58

Total Value Per Share

$-12.45 - $13.48

2. Growth of Aytu BioScience Inc (5 min.)




Is Aytu BioScience Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$32.8m$51.7m-$13.6m-35.7%

How much money is Aytu BioScience Inc making?

Current yearPrevious yearGrowGrow %
Making money-$2.7m-$48.2m$45.4m1,657.8%
Net Profit Margin-10.7%-193.3%--

How much money comes from the company's main activities?

3. Financial Health of Aytu BioScience Inc (5 min.)




What can you expect buying and holding a share of Aytu BioScience Inc? (5 min.)

Welcome investor! Aytu BioScience Inc's management wants to use your money to grow the business. In return you get a share of Aytu BioScience Inc.

What can you expect buying and holding a share of Aytu BioScience Inc?

First you should know what it really means to hold a share of Aytu BioScience Inc. And how you can make/lose money.

Speculation

The Price per Share of Aytu BioScience Inc is $2.84. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aytu BioScience Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aytu BioScience Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.90. Based on the TTM, the Book Value Change Per Share is $-0.58 per quarter. Based on the YOY, the Book Value Change Per Share is $-2.68 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aytu BioScience Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.04-1.4%-0.60-21.0%-3.61-127.0%-2.00-70.3%-1.45-51.0%
Usd Book Value Change Per Share-1.17-41.1%-0.58-20.5%-2.68-94.4%0.124.1%0.155.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.17-41.1%-0.58-20.5%-2.68-94.4%0.124.1%0.155.2%
Usd Price Per Share2.84-2.34-0.54-2.21-1.56-
Price to Earnings Ratio-17.97--5.15--0.05--1.62--2.82-
Price-to-Total Gains Ratio-2.43--3.57--0.10--1.01--8.14-
Price to Book Ratio0.48-0.35-0.06-0.41--0.48-
Price-to-Total Gains Ratio-2.43--3.57--0.10--1.01--8.14-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.84
Number of shares352
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.580.12
Usd Total Gains Per Share-0.580.12
Gains per Quarter (352 shares)-204.9140.95
Gains per Year (352 shares)-819.62163.81
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-820-8300164154
20-1639-16500328318
30-2459-24700491482
40-3278-32900655646
50-4098-41100819810
60-4918-49300983974
70-5737-5750011471138
80-6557-6570013101302
90-7377-7390014741466
100-8196-8210016381630

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%1.067.00.01.5%
Book Value Change Per Share0.03.01.00.0%2.09.01.016.7%6.013.01.030.0%17.022.01.042.5%21.043.04.030.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.039.02.5%1.00.067.01.5%
Total Gains per Share0.03.01.00.0%2.09.01.016.7%6.013.01.030.0%17.022.01.042.5%21.043.04.030.9%

Fundamentals of Aytu BioScience Inc

About Aytu BioScience Inc

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.

Fundamental data was last updated by Penke on 2024-04-11 01:47:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Aytu BioScience Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Aytu BioScience Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aytu BioScience Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -1.0% means that $-0.01 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aytu BioScience Inc:

  • The MRQ is -1.0%. The company is not making a profit/loss.
  • The TTM is -10.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1.0%TTM-10.7%+9.7%
TTM-10.7%YOY-193.3%+182.6%
TTM-10.7%5Y-140.9%+130.3%
5Y-140.9%10Y-579.1%+438.2%
1.1.2. Return on Assets

Shows how efficient Aytu BioScience Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aytu BioScience Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.2% Return on Assets means that Aytu BioScience Inc generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aytu BioScience Inc:

  • The MRQ is -0.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.2%TTM-1.9%+1.8%
TTM-1.9%YOY-30.2%+28.3%
TTM-1.9%5Y-12.3%+10.3%
5Y-12.3%10Y-35.1%+22.8%
1.1.3. Return on Equity

Shows how efficient Aytu BioScience Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aytu BioScience Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.7% Return on Equity means Aytu BioScience Inc generated $-0.01 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aytu BioScience Inc:

  • The MRQ is -0.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -6.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.7%TTM-6.9%+6.2%
TTM-6.9%YOY-85.6%+78.8%
TTM-6.9%5Y-45.3%+38.4%
5Y-45.3%10Y-50.3%+5.0%

1.2. Operating Efficiency of Aytu BioScience Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Aytu BioScience Inc is operating .

  • Measures how much profit Aytu BioScience Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aytu BioScience Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.8% means the company generated $0.01  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aytu BioScience Inc:

  • The MRQ is 0.8%. The company is operating inefficient. -1
  • The TTM is -2.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ0.8%TTM-2.2%+3.0%
TTM-2.2%YOY32.3%-34.5%
TTM-2.2%5Y-37.2%+35.1%
5Y-37.2%10Y-280.4%+243.2%
1.2.2. Operating Ratio

Measures how efficient Aytu BioScience Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.84 means that the operating costs are $0.84 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aytu BioScience Inc:

  • The MRQ is 0.840. The company is less efficient in keeping operating costs low.
  • The TTM is 1.116. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.840TTM1.116-0.275
TTM1.116YOY1.217-0.102
TTM1.1165Y1.772-0.656
5Y1.77210Y169.206-167.434

1.3. Liquidity of Aytu BioScience Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Aytu BioScience Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.11 means the company has $1.11 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aytu BioScience Inc:

  • The MRQ is 1.112. The company is just able to pay all its short-term debts.
  • The TTM is 1.035. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.112TTM1.035+0.077
TTM1.035YOY0.992+0.043
TTM1.0355Y1.650-0.614
5Y1.65010Y1.886-0.237
1.3.2. Quick Ratio

Measures if Aytu BioScience Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aytu BioScience Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.76 means the company can pay off $0.76 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aytu BioScience Inc:

  • The MRQ is 0.762. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.639. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.762TTM0.639+0.123
TTM0.639YOY0.676-0.036
TTM0.6395Y1.225-0.586
5Y1.22510Y1.535-0.309

1.4. Solvency of Aytu BioScience Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Aytu BioScience Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aytu BioScience Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.75 means that Aytu BioScience Inc assets are financed with 75.0% credit (debt) and the remaining percentage (100% - 75.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aytu BioScience Inc:

  • The MRQ is 0.750. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.724. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.750TTM0.724+0.026
TTM0.724YOY0.655+0.069
TTM0.7245Y0.606+0.118
5Y0.60610Y1.637-1.031
1.4.2. Debt to Equity Ratio

Measures if Aytu BioScience Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aytu BioScience Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 299.5% means that company has $3.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aytu BioScience Inc:

  • The MRQ is 2.995. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.632. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.995TTM2.632+0.363
TTM2.632YOY1.904+0.728
TTM2.6325Y2.284+0.348
5Y2.28410Y2.089+0.195

2. Market Valuation of Aytu BioScience Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aytu BioScience Inc generates.

  • Above 15 is considered overpriced but always compare Aytu BioScience Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -17.97 means the investor is paying $-17.97 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aytu BioScience Inc:

  • The EOD is -17.968. Based on the earnings, the company is expensive. -2
  • The MRQ is -17.968. Based on the earnings, the company is expensive. -2
  • The TTM is -5.152. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-17.968MRQ-17.9680.000
MRQ-17.968TTM-5.152-12.817
TTM-5.152YOY-0.053-5.099
TTM-5.1525Y-1.617-3.535
5Y-1.61710Y-2.818+1.201
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aytu BioScience Inc:

  • The EOD is -29.281. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -29.281. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.429. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-29.281MRQ-29.2810.000
MRQ-29.281TTM-7.429-21.853
TTM-7.429YOY-0.109-7.320
TTM-7.4295Y-1.989-5.439
5Y-1.98910Y-3.977+1.988
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Aytu BioScience Inc is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Aytu BioScience Inc:

  • The EOD is 0.481. Based on the equity, the company is cheap. +2
  • The MRQ is 0.481. Based on the equity, the company is cheap. +2
  • The TTM is 0.349. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.481MRQ0.4810.000
MRQ0.481TTM0.349+0.133
TTM0.349YOY0.056+0.293
TTM0.3495Y0.413-0.065
5Y0.41310Y-0.484+0.897
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aytu BioScience Inc.

3.1. Institutions holding Aytu BioScience Inc

Institutions are holding 31.779% of the shares of Aytu BioScience Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Nantahala Capital Management, LLC39.04060.184621736241086812100
2023-12-31Stonepine Capital Management Llc8.4860.58034724691000.0212
2023-12-31Renaissance Technologies Corp1.23790.000368923820013.5039
2023-12-31Geode Capital Management, LLC0.59350330461651199.8549
2023-12-31Goldman Sachs Group Inc0.4987027764277640
2023-12-31Vanguard Group Inc0.489502725114278110.0594
2023-12-31BlackRock Inc0.4094022793-1266-5.2621
2023-12-31Acadian Asset Management LLC0.26260.000214622-7915-35.12
2023-12-31Northern Trust Corp0.261701456800
2023-12-31JPMorgan Chase & Co0.1228068354647212.3857
2023-12-31Royal Bank of Canada0.06460359935990
2023-12-31Tower Research Capital LLC0.0410.00012283-3471-60.3233
2023-12-31Morgan Stanley - Brokerage Accounts0.02510140000
2023-12-31Advisor Group Holdings, Inc.0.00540300-1-0.3322
2023-09-30Ronald Blue Trust, Inc.0.00502782780
2023-12-31UBS Group AG0.00470260-3904-93.756
2023-12-31Wells Fargo & Co0.00310171148.9172
2023-12-31Group One Trading, LP0.000703700
2023-12-31Goss Wealth Management LLC0.000402100
2023-12-31CarsonAllaria Wealth Management, Ltd.0.00010500
Total 51.55280.76552870249+1145646+39.9%

3.2. Funds holding Aytu BioScience Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Extended Market Index0.53320.000229685-144-0.4828
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.4990.0001277825311.9486
2023-12-31Northern Trust Extended Eq Market Idx0.11340.0003631100
2023-12-31NT Ext Equity Mkt Idx Fd - L0.11340.0003631100
2023-09-30BlackRock Extended Mkt Composite0.07330.0001408300
2024-03-31BlackRock Extended Equity Market K0.0640.0001356310.0281
2024-02-29DFA US Micro Cap I0.0580.0001322800
2024-02-29Fidelity Series Total Market Index0.05590311000
2024-02-29Fidelity Total Market Index0.02850158900
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.02250.0001125200
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.01810.0001100620.1992
2024-03-29Dimensional US Core Equity 2 ETF0.016089000
2024-03-31Extended Equity Market Fund M0.00790.0001440-1-0.2268
2024-02-29Spartan Extended Market Index Pool E0.002601441440
2023-12-31SSgA U.S. Extended Market Index Class I0.0023012900
2024-03-31State St US Extended Mkt Indx NL Cl C0.0023012900
2023-12-31NT US Market Cap Idx Fd - L0.0018010300
2023-12-31Northern Trust Wilshire 50000.0018010300
2023-12-31BNYM Mellon SL Market Completion UC10.00130.000173-1-1.3514
2024-02-29Acapital Fertility And Genomics A FI0.00130.02217100
Total 1.61660.023790002+532+0.6%

3.3. Insider Transactions

Insiders are holding 3.484% of the shares of Aytu BioScience Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-06-16Greg PyszczymukaBUY120001.87
2023-06-14Joshua R DisbrowBUY140001.86

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Aytu BioScience Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.168-0.582-50%-2.682+130%0.116-1104%0.148-889%
Book Value Per Share--5.9016.847-14%9.293-37%11.093-47%6.300-6%
Current Ratio--1.1121.035+7%0.992+12%1.650-33%1.886-41%
Debt To Asset Ratio--0.7500.724+4%0.655+14%0.606+24%1.637-54%
Debt To Equity Ratio--2.9952.632+14%1.904+57%2.284+31%2.089+43%
Dividend Per Share----0%-0%-0%0.000-100%
Eps---0.040-0.595+1406%-3.608+9030%-1.995+4950%-1.447+3563%
Free Cash Flow Per Share---0.0240.704-103%-1.248+5048%-0.731+2913%-0.599+2371%
Free Cash Flow To Equity Per Share---0.0470.329-114%-0.705+1404%0.222-121%0.270-117%
Gross Profit Margin--30.8919.833+214%1.933+1498%3.045+914%2.055+1403%
Intrinsic Value_10Y_max--7.577--------
Intrinsic Value_10Y_min---18.351--------
Intrinsic Value_1Y_max---1.930--------
Intrinsic Value_1Y_min---2.316--------
Intrinsic Value_3Y_max---3.749--------
Intrinsic Value_3Y_min---6.588--------
Intrinsic Value_5Y_max---3.098--------
Intrinsic Value_5Y_min---10.418--------
Market Cap15811984.0000%15811984.00013055882.810+21%2984233.600+430%12801539.417+24%8953709.175+77%
Net Profit Margin---0.010-0.107+1011%-1.933+20047%-1.409+14590%-5.791+60267%
Operating Margin--0.008-0.022+370%0.323-98%-0.372+4716%-2.804+34862%
Operating Ratio--0.8401.116-25%1.217-31%1.772-53%169.206-100%
Pb Ratio0.4810%0.4810.349+38%0.056+760%0.413+17%-0.484+201%
Pe Ratio-17.9680%-17.968-5.152-71%-0.053-100%-1.617-91%-2.818-84%
Price Per Share2.8400%2.8402.345+21%0.536+430%2.210+29%1.563+82%
Price To Free Cash Flow Ratio-29.2810%-29.281-7.429-75%-0.109-100%-1.989-93%-3.977-86%
Price To Total Gains Ratio-2.4310%-2.431-3.567+47%-0.097-96%-1.014-58%-8.141+235%
Quick Ratio--0.7620.639+19%0.676+13%1.225-38%1.535-50%
Return On Assets---0.002-0.019+1054%-0.302+17931%-0.123+7223%-0.351+20850%
Return On Equity---0.007-0.069+924%-0.856+12686%-0.453+6658%-0.503+7409%
Total Gains Per Share---1.168-0.582-50%-2.682+130%0.116-1104%0.148-888%
Usd Book Value--32853000.00038119750.000-14%51739750.000-37%64407889.250-49%36402793.125-10%
Usd Book Value Change Per Share---1.168-0.582-50%-2.682+130%0.116-1104%0.148-889%
Usd Book Value Per Share--5.9016.847-14%9.293-37%11.093-47%6.300-6%
Usd Dividend Per Share----0%-0%-0%0.000-100%
Usd Eps---0.040-0.595+1406%-3.608+9030%-1.995+4950%-1.447+3563%
Usd Free Cash Flow---135000.0003922250.000-103%-6949500.000+5048%-4284036.800+3073%-3443746.900+2451%
Usd Free Cash Flow Per Share---0.0240.704-103%-1.248+5048%-0.731+2913%-0.599+2371%
Usd Free Cash Flow To Equity Per Share---0.0470.329-114%-0.705+1404%0.222-121%0.270-117%
Usd Market Cap15811984.0000%15811984.00013055882.810+21%2984233.600+430%12801539.417+24%8953709.175+77%
Usd Price Per Share2.8400%2.8402.345+21%0.536+430%2.210+29%1.563+82%
Usd Profit---220000.000-2744000.000+1147%-48233500.000+21824%-16654281.200+7470%-10060355.650+4473%
Usd Revenue--22934000.00026782750.000-14%26395250.000-13%17821579.900+29%9234018.475+148%
Usd Total Gains Per Share---1.168-0.582-50%-2.682+130%0.116-1104%0.148-888%
 EOD+0 -0MRQTTM+17 -17YOY+24 -105Y+18 -1610Y+20 -16

4.2. Fundamental Score

Let's check the fundamental score of Aytu BioScience Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-17.968
Price to Book Ratio (EOD)Between0-10.481
Net Profit Margin (MRQ)Greater than0-0.010
Operating Margin (MRQ)Greater than00.008
Quick Ratio (MRQ)Greater than10.762
Current Ratio (MRQ)Greater than11.112
Debt to Asset Ratio (MRQ)Less than10.750
Debt to Equity Ratio (MRQ)Less than12.995
Return on Equity (MRQ)Greater than0.15-0.007
Return on Assets (MRQ)Greater than0.05-0.002
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Aytu BioScience Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.135
Ma 20Greater thanMa 502.983
Ma 50Greater thanMa 1003.000
Ma 100Greater thanMa 2002.852
OpenGreater thanClose2.790
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Income before Tax  -6,693-507-7,2004,743-2,4570-2,4573,065608



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets131,249
Total Liabilities98,396
Total Stockholder Equity32,853
 As reported
Total Liabilities 98,396
Total Stockholder Equity+ 32,853
Total Assets = 131,249

Assets

Total Assets131,249
Total Current Assets71,371
Long-term Assets59,878
Total Current Assets
Cash And Cash Equivalents 19,529
Net Receivables 29,403
Inventory 13,001
Other Current Assets 1,333
Total Current Assets  (as reported)71,371
Total Current Assets  (calculated)63,266
+/- 8,105
Long-term Assets
Property Plant Equipment 3,260
Intangible Assets 55,711
Long-term Assets Other 907
Long-term Assets  (as reported)59,878
Long-term Assets  (calculated)59,878
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities64,187
Long-term Liabilities34,209
Total Stockholder Equity32,853
Total Current Liabilities
Short-term Debt 1,065
Short Long Term Debt 1,065
Accounts payable 10,473
Other Current Liabilities 9,236
Total Current Liabilities  (as reported)64,187
Total Current Liabilities  (calculated)21,839
+/- 42,348
Long-term Liabilities
Long term Debt 14,978
Long-term Liabilities Other 6,344
Long-term Liabilities  (as reported)34,209
Long-term Liabilities  (calculated)21,322
+/- 12,887
Total Stockholder Equity
Common Stock1
Retained Earnings -312,469
Other Stockholders Equity 345,321
Total Stockholder Equity (as reported)32,853
Total Stockholder Equity (calculated)32,853
+/-0
Other
Capital Stock1
Cash and Short Term Investments 19,529
Common Stock Shares Outstanding 5,518
Current Deferred Revenue43,413
Liabilities and Stockholders Equity 131,249
Net Debt -3,486
Net Invested Capital 48,896
Net Working Capital 7,184
Property Plant and Equipment Gross 6,338
Short Long Term Debt Total 16,043



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-03-31
> Total Assets 
68
68
68
68
68
60
108
95
82
74
53
43
43
42
30
26
36
27
25
28
28
23
16
16
13
13
12
13
9
10
7
6
13
6
11
10,201
18,227
21,359
24,410
21,986
24,343
20,201
21,506
15,917
14,999
21,246
18,858
23,375
21,060
17,985
42,399
38,338
34,721
31,024
74,478
158,954
152,836
152,836
166,742
271,557
265,668
227,729
223,824
168,826
137,623
150,000
141,436
147,216
136,463
136,463
131,249
131,249136,463136,463147,216141,436150,000137,623168,826223,824227,729265,668271,557166,742152,836152,836158,95474,47831,02434,72138,33842,39917,98521,06023,37518,85821,24614,99915,91721,50620,20124,34321,98624,41021,35918,22710,2011161367109131213131616232828252736263042434353748295108606868686868
   > Total Current Assets 
0
0
0
30
30
23
69
58
44
38
18
10
13
14
4
1
8
2
1
6
8
4
1
1
0
0
1
3
1
2
1
0
9
2
9
1,650
8,084
11,308
12,765
10,437
10,120
6,364
8,158
4,438
3,029
9,742
7,745
14,595
9,470
6,872
21,977
18,459
15,433
11,983
18,338
83,255
74,966
74,966
92,537
100,013
105,234
89,038
87,540
77,947
59,929
74,415
70,611
78,465
72,832
72,832
71,371
71,37172,83272,83278,46570,61174,41559,92977,94787,54089,038105,234100,01392,53774,96674,96683,25518,33811,98315,43318,45921,9776,8729,47014,5957,7459,7423,0294,4388,1586,36410,12010,43712,76511,3088,0841,6509290121310011486128141413101838445869233030000
       Cash And Cash Equivalents 
0
0
0
29
29
23
69
58
44
38
18
10
13
14
3
0
8
2
1
6
7
4
1
1
0
0
1
3
1
2
0
0
9
2
9
1,491
7,353
10,069
10,960
8,666
8,054
2,749
5,230
3,470
802
7,022
3,908
12,006
7,013
3,965
17,805
14,647
11,044
7,014
5,259
62,265
48,082
48,082
62,033
46,538
49,649
40,308
35,277
27,613
19,360
23,811
19,501
19,179
22,985
22,985
19,529
19,52922,98522,98519,17919,50123,81119,36027,61335,27740,30849,64946,53862,03348,08248,08262,2655,2597,01411,04414,64717,8053,9657,01312,0063,9087,0228023,4705,2302,7498,0548,66610,96010,0697,3531,4919290021310011476128031413101838445869232929000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,041
1,769
1,272
75
75
75
76
76
100
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000010010076767575751,2721,7691,0410000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
157
168
288
84
162
509
582
343
528
1,212
1,377
732
579
760
1,482
1,376
1,741
2,705
6,547
10,203
5,176
5,176
7,001
28,228
28,176
21,626
22,989
27,613
21,712
27,924
25,547
34,043
28,937
28,937
29,403
29,40328,93728,93734,04325,54727,92421,71227,61322,98921,62628,17628,2287,0015,1765,17610,2036,5472,7051,7411,3761,4827605797321,3771,21252834358250916284288168157110000000000000110000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
147
7
534
577
864
1,065
338
750
634
417
386
337
1,079
973
540
837
1,045
905
1,208
59
1,427
1,850
11,709
5,742
10,599
1,615
1,038
1,195
1,418
888
633
785
624
1,177
868
868
1,333
1,3338688681,1776247856338881,4181,1951,0381,61510,5995,74211,7091,8501,427591,2089051,0458375409731,0793373864176347503381,06586457753471470000000000000000000000000000000000
   > Long-term Assets 
0
0
0
38
38
36
38
37
38
36
35
32
30
28
26
25
28
25
24
22
20
19
15
15
0
12
11
10
9
8
7
5
4
3
2
8,551
10,143
10,052
11,645
11,549
14,223
13,837
13,348
11,478
11,970
11,504
11,114
8,780
11,590
11,113
20,422
19,879
19,289
19,041
56,140
75,699
77,871
77,871
74,205
171,544
160,434
138,691
136,284
90,879
77,694
75,585
70,825
68,751
63,631
63,631
59,878
59,87863,63163,63168,75170,82575,58577,69490,879136,284138,691160,434171,54474,20577,87177,87175,69956,14019,04119,28919,87920,42211,11311,5908,78011,11411,50411,97011,47813,34813,83714,22311,54911,64510,05210,1438,55123457891011120151519202224252825262830323536383738363838000
       Property Plant Equipment 
0
0
0
38
38
36
38
37
38
36
35
32
30
28
26
25
28
25
24
22
20
19
15
15
12
12
11
10
8
8
6
5
4
3
2
37
30
26
144
197
231
313
292
271
647
567
561
261
219
196
187
219
204
532
497
964
259
893
400
9,340
8,703
8,492
8,139
7,040
6,296
5,648
5,019
4,395
3,869
3,869
3,260
3,2603,8693,8694,3955,0195,6486,2967,0408,1398,4928,7039,340400893259964497532204219187196219261561567647271292313231197144263037234568810111212151519202224252825262830323536383738363838000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
74
74
221
221
221
221
221
74
238
238
238
0
0
0
0
0
0
0
15,387
24,061
28,090
28,090
28,090
65,803
65,802
46,349
46,349
8,637
0
0
0
0
0
0
0
00000008,63746,34946,34965,80265,80328,09028,09028,09024,06115,3870000000238238238742212212212212217474000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,200
0
8,146
8,146
9,699
9,641
11,003
10,885
13,554
13,117
12,680
11,131
11,081
10,696
10,312
8,516
11,366
10,914
20,233
19,658
19,083
18,507
40,254
50,634
48,855
48,855
45,699
96,237
85,464
83,385
81,339
74,428
70,632
69,108
64,985
63,464
58,970
58,970
55,711
55,71158,97058,97063,46464,98569,10870,63274,42881,33983,38585,46496,23745,69948,85548,85550,63440,25418,50719,08319,65820,23310,91411,3668,51610,31210,69611,08111,13112,68013,11713,55410,88511,0039,6419,6998,1468,14608,20000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,657
0
398
0
10,113
10,025
11,501
11,352
13,992
13,524
13,056
11,208
11,323
10,937
10,552
3
5
2
2
2
2
2
2
39
33
10
16
165
465
465
457
774
766
829
821
0
792
772
0
07727920821829766774457465465165161033392222225310,55210,93711,32311,20813,05613,52413,99211,35211,50110,02510,113039808,65700000000000000000000000000000000
> Total Liabilities 
0
0
0
39
39
41
43
40
44
48
50
52
55
55
61
68
84
83
92
53
66
58
66
66
82
82
94
108
115
121
133
153
50
51
55
9,650
2,610
7,951
9,151
4,420
14,258
13,014
11,059
7,395
10,999
14,893
15,828
10,624
7,636
7,855
22,501
22,301
27,634
28,700
57,387
73,250
57,821
57,821
54,049
128,407
128,100
116,229
118,288
107,682
91,531
96,094
95,619
106,304
97,106
97,106
98,396
98,39697,10697,106106,30495,61996,09491,531107,682118,288116,229128,100128,40754,04957,82157,82173,25057,38728,70027,63422,30122,5017,8557,63610,62415,82814,89310,9997,39511,05913,01414,2584,4209,1517,9512,6109,650555150153133121115108948282666658665392838468615555525048444043413939000
   > Total Current Liabilities 
0
0
0
39
39
41
43
40
44
48
50
52
55
55
61
68
84
83
92
53
66
58
66
66
82
82
94
108
115
121
133
153
50
51
55
9,203
1,479
1,778
2,804
3,205
10,104
8,731
6,972
3,354
3,610
3,508
4,801
4,342
3,395
3,587
4,655
4,504
5,373
6,102
15,949
42,033
28,307
28,307
25,813
83,683
109,438
97,997
100,571
80,360
64,442
73,204
67,150
85,416
69,015
69,015
64,187
64,18769,01569,01585,41667,15073,20464,44280,360100,57197,997109,43883,68325,81328,30728,30742,03315,9496,1025,3734,5044,6553,5873,3954,3424,8013,5083,6103,3546,9728,73110,1043,2052,8041,7781,4799,203555150153133121115108948282666658665392838468615555525048444043413939000
       Short-term Debt 
0
0
0
34
34
34
34
34
38
48
49
0
55
55
0
0
78
78
0
59
59
52
0
55
68
68
83
83
96
100
105
113
29
31
32
8,514
0
0
1,292
1,221
276
347
80
0
0
0
0
0
0
0
1,677
0
0
79
83
3,907
1,492
1,283
854
7,032
25,542
22,112
24,725
4,688
3,909
9,012
7,519
13,708
0
1,648
1,065
1,0651,648013,7087,5199,0123,9094,68824,72522,11225,5427,0328541,2831,4923,9078379001,6770000000803472761,2211,292008,51432312911310510096838368685505259590787800555504948383434343434000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,700
0
0
0
0
0
5,380
0
4,000
0
0
0
0
0
0
0
0
0
0
0
263
4,559
1,492
1,582
753
6,121
24,602
21,028
23,552
3,485
3,909
9,012
7,519
13,708
1,648
1,277
1,065
1,0651,2771,64813,7087,5199,0123,9093,48523,55221,02824,6026,1217531,5821,4924,559263000000000004,00005,380000005,7000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
2
2
3
0
6
0
0
0
0
0
4
3
0
0
3
0
1
0
4
4
0
6
12
14
121
7
13
11
3
0
4
546
1,197
1,075
1,076
1,177
3,520
2,508
2,446
1,409
2,220
1,661
3,415
3,199
2,120
2,112
2,372
2,131
2,297
2,633
9,599
6,956
22,792
11,825
7,157
16,529
19,255
9,383
15,604
11,130
10,987
14,667
10,580
14,673
13,478
13,478
10,473
10,47313,47813,47814,67310,58014,66710,98711,13015,6049,38319,25516,5297,15711,82522,7926,9569,5992,6332,2972,1312,3722,1122,1203,1993,4151,6612,2201,4092,4462,5083,5201,1771,0761,0751,19754640311137121141260440103003400000603220000
       Other Current Liabilities 
0
0
0
4
4
5
6
6
1
1
0
52
55
1
57
65
84
5
90
53
7
6
62
62
0
8
11
94
0
14
29
142
18
19
-66
57
197
617
1,642
1,943
6,585
6,223
4,526
1,945
1,390
1,847
1,386
1,143
1,275
1,475
593
2,373
3,075
3,311
3,367
30,990
2,193
14,860
17,327
7,087
7,407
7,360
4,516
64,542
49,546
49,425
48,951
57,035
28,606
7,090
9,236
9,2367,09028,60657,03548,95149,42549,54664,5424,5167,3607,4077,08717,32714,8602,19330,9903,3673,3113,0752,3735931,4751,2751,1431,3861,8471,3901,9454,5266,2236,5851,9431,64261719757-66191814229140941180626267539058465571555201166544000
   > Long-term Liabilities 
0
0
0
0
34
36
34
34
44
48
0
0
0
55
3
3
0
78
3
0
59
53
0
60
0
74
97
104
0
106
124
124
32
31
447
447
1,131
6,173
6,347
1,215
4,153
4,283
4,088
4,041
7,388
11,385
11,027
6,282
4,241
4,267
17,846
17,797
22,261
22,598
41,438
31,217
29,514
29,514
28,236
44,724
18,662
18,232
17,717
27,322
27,089
22,890
28,469
20,888
28,091
28,091
34,209
34,20928,09128,09120,88828,46922,89027,08927,32217,71718,23218,66244,72428,23629,51429,51431,21741,43822,59822,26117,79717,8464,2674,2416,28211,02711,3857,3884,0414,0884,2834,1531,2156,3476,1731,131447447313212412410601049774060053590378033550004844343436340000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,825
0
0
0
0
0
0
0
0
0
0
0
0
5,036
5,135
0
0
23,395
8,162
11,171
10,680
9,946
0
0
0
0
0
0
0
0
0
0
0
0
0000000000009,94610,68011,1718,16223,395005,1355,0360000000000004,8250000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
512
0
469
0
1,091
1,253
1,425
1,205
4,153
4,283
4,087
4,041
7,389
11,385
11,026
6,282
4,241
4,267
12,810
12,662
22,261
22,283
41,146
30,413
28,789
28,465
28,025
24,922
15,858
15,320
14,872
10,749
12,810
9,330
12,465
0
13,378
20,415
0
020,41513,378012,4659,33012,81010,74914,87215,32015,85824,92228,02528,46528,78930,41341,14622,28322,26112,66212,8104,2674,2416,28211,02611,3857,3894,0414,0874,2834,1531,2051,4251,2531,0910469051200000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
396
447
467
613
0
0
213
0
5
3
1
3,818
3,300
120
94
47
26
29
13
11
11
11
11
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000001111111113292647941203,3003,8181350213006134674473960000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
29
29
19
64
55
38
26
0
-10
-12
-14
-32
-42
-48
-56
-67
-24
-38
-36
-49
-49
0
-70
-82
-95
-111
-111
-126
-148
-36
-45
-44
551
15,616
13,409
15,259
17,566
10,085
7,187
10,447
8,521
4,000
6,353
3,031
12,750
13,425
10,130
19,898
16,037
7,088
2,324
17,090
85,704
95,015
95,015
112,693
143,150
137,568
111,500
105,536
61,144
46,092
53,906
45,817
40,912
39,357
39,357
32,853
32,85339,35739,35740,91245,81753,90646,09261,144105,536111,500137,568143,150112,69395,01595,01585,70417,0902,3247,08816,03719,89810,13013,42512,7503,0316,3534,0008,52110,4477,18710,08517,56615,25913,40915,616551-44-45-36-148-126-111-111-95-82-700-49-49-36-38-24-67-56-48-42-32-14-12-10026385564192929000
   Common Stock
0
0
0
0
0
0
0
0
205
205
0
0
0
0
0
0
0
1
0
0
0
395
0
2
0
0
412
412
414
414
417
417
540
540
555
4
1
1
1
2
0
1
1
1
0
0
0
4
0
0
1
1
2
2
2
10
13
13
2
2
3
3
3
3
4
6
0
0
1
1
1
11100643333221313102221100400011102111455554054041741741441441241200203950001000000020520500000000
   Retained Earnings Total Equity00000000000-159,301-133,841-124,316-120,010-116,865-111,533-111,319-106,390-91,858-87,362-82,704-79,258-79,805-76,987-73,315-69,070-62,319-57,103-52,286-46,561-31,264-23,990-20,658-18,381-12,610-656-6460-619-607-585-569000000-1000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
1
1
1
0
-23
-1
-1
-1
-1
-1
0
-314
0
0
-47
-451
-481
-481
-53
-511
-531
0
-58
-58
0
0
-63
-63
-53
-53
-5,000
-5,000
-79
-97
-112
-130
-157
-184
-246
-326
-407
-498
-540
-350
-366
-381
-396
-412
-428
-1,219
-484
-484
-504
-571
0
0
0
0
0
0
0
0
0
0
0
00000000000-571-504-484-484-1,219-428-412-396-381-366-350-540-498-407-326-246-184-157-130-112-97-79-5,000-5,000-53-53-63-6300-58-580-531-511-53-481-481-451-4700-3140-1-1-1-1-1-230111000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29
0
0
0
0
0
0
41
42
43
43
0
47
48
13,157
38,996
39,065
39,247
48,827
56,646
59,472
67,549
70,839
73,069
79,667
80,018
92,552
92,682
92,834
107,258
107,893
113,475
113,640
128,620
202,558
215,013
215,366
246,532
302,448
0
0
0
0
0
0
0
0
0
0
0
00000000000302,448246,532215,366215,013202,558128,620113,640113,475107,893107,25892,83492,68292,55280,01879,66773,06970,83967,54959,47256,64648,82739,24739,06538,99613,157484704343424100000029000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
155
155
157
218
219
220
16
0
225
232
242
243
245
253
259
265
335
342
416
432
431
0
442
38
38
3
102
42
43
43
109
13,210
13,157
38,996
39,065
39,326
48,924
56,758
59,602
67,706
71,023
73,315
79,993
80,425
93,050
93,222
93,184
107,624
108,274
113,871
114,052
129,048
202,558
0
215,013
246,532
302,448
315,864
317,647
323,231
331,912
334,560
345,253
340,289
342,584
0
343,485
345,321
345,321343,4850342,584340,289345,253334,560331,912323,231317,647315,864302,448246,532215,0130202,558129,048114,052113,871108,274107,62493,18493,22293,05080,42579,99373,31571,02367,70659,60256,75848,92439,32639,06538,99613,15713,210109434342102338384420431432416342335265259253245243242232225016220219218157155155000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-06-30)

Gross Profit (+$)
totalRevenue107,399
Cost of Revenue-40,767
Gross Profit66,63266,632
 
Operating Income (+$)
Gross Profit66,632
Operating Expense-78,961
Operating Income-17,065-12,329
 
Operating Expense (+$)
Research Development4,095
Selling General Administrative28,630
Selling And Marketing Expenses41,448
Operating Expense78,96174,173
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-17,065
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-17,051-12,343
EBIT - interestExpense = -12,386
-17,108
-17,051
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-12,386-17,051
Earnings Before Interest and Taxes (EBITDA)-7,598
 
After tax Income (+$)
Income Before Tax-17,051
Tax Provision-0
Net Income From Continuing Ops-17,051-17,051
Net Income-17,051
Net Income Applicable To Common Shares-17,051
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses119,728
Total Other Income/Expenses Net-4,7220
 

Technical Analysis of Aytu BioScience Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aytu BioScience Inc. The general trend of Aytu BioScience Inc is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aytu BioScience Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aytu BioScience Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.38 < 3.38 < 3.45.

The bearish price targets are: 2.65 > 2.48 > 2.37.

Tweet this
Aytu BioScience Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aytu BioScience Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aytu BioScience Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aytu BioScience Inc. The current macd is -0.06460688.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aytu BioScience Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aytu BioScience Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aytu BioScience Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Aytu BioScience Inc Daily Moving Average Convergence/Divergence (MACD) ChartAytu BioScience Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aytu BioScience Inc. The current adx is 20.29.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Aytu BioScience Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Aytu BioScience Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aytu BioScience Inc. The current sar is 3.15677077.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Aytu BioScience Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aytu BioScience Inc. The current rsi is 45.14. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Aytu BioScience Inc Daily Relative Strength Index (RSI) ChartAytu BioScience Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aytu BioScience Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aytu BioScience Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Aytu BioScience Inc Daily Stochastic Oscillator ChartAytu BioScience Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aytu BioScience Inc. The current cci is -68.64311044.

Aytu BioScience Inc Daily Commodity Channel Index (CCI) ChartAytu BioScience Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aytu BioScience Inc. The current cmo is -10.23157922.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Aytu BioScience Inc Daily Chande Momentum Oscillator (CMO) ChartAytu BioScience Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aytu BioScience Inc. The current willr is -72.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Aytu BioScience Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Aytu BioScience Inc Daily Williams %R ChartAytu BioScience Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aytu BioScience Inc.

Aytu BioScience Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aytu BioScience Inc. The current atr is 0.16721057.

Aytu BioScience Inc Daily Average True Range (ATR) ChartAytu BioScience Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aytu BioScience Inc. The current obv is 3,499,322.

Aytu BioScience Inc Daily On-Balance Volume (OBV) ChartAytu BioScience Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aytu BioScience Inc. The current mfi is 35.63.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Aytu BioScience Inc Daily Money Flow Index (MFI) ChartAytu BioScience Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aytu BioScience Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Aytu BioScience Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aytu BioScience Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.135
Ma 20Greater thanMa 502.983
Ma 50Greater thanMa 1003.000
Ma 100Greater thanMa 2002.852
OpenGreater thanClose2.790
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Aytu BioScience Inc with someone you think should read this too:
  • Are you bullish or bearish on Aytu BioScience Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aytu BioScience Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aytu BioScience Inc

I send you an email if I find something interesting about Aytu BioScience Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aytu BioScience Inc.

Receive notifications about Aytu BioScience Inc in your mailbox!